Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;35(3):100626.
doi: 10.1016/j.trre.2021.100626. Epub 2021 May 4.

The potential of biomarkers of fibrosis in chronic lung allograft dysfunction

Eline A van der Ploeg  1 , Barbro N Melgert  2 , Janette K Burgess  3 , C Tji Gan  4
Affiliations
Free article
Review

The potential of biomarkers of fibrosis in chronic lung allograft dysfunction

Eline A van der Ploeg et al. Transplant Rev (Orlando). 2021 Jul.
Free article

Abstract

Chronic lung allograft dysfunction (CLAD) is the major long-term cause of morbidity and mortality after lung transplantation. Both bronchiolitis obliterans syndrome and restrictive lung allograft syndrome, two main types of CLAD, lead to fibrosis in either the small airways or alveoli and pleura. Pathological pathways in CLAD and other types of fibrosis, for example idiopathic pulmonary fibrosis, are assumed to overlap and therefore fibrosis biomarkers could aid in the early detection of CLAD. These biomarkers could help to differentiate between different phenotypes of CLAD and could, in comparison to biomarkers of inflammation, possibly distinguish an infectious event from CLAD when a decline in lung function is present. This review gives an overview of known CLAD specific biomarkers, describes new promising fibrosis biomarkers currently investigated in other types of fibrosis, and discusses the possible use of these fibrosis biomarkers for CLAD.

Keywords: BOS; Biomarker; CLAD; Fibrosis; Lung transplantation; RAS.

PubMed Disclaimer